{"name":"Exonate Limited","slug":"exonate-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQdDdkd25rbXF2Y2VkUFQ1Yktqak9BQVZiTngwNE91eDhuaHhubkIxY0pYaGNvLUtoVGJpYlBrR1g2XzBRYldVRFlyOGZJU1lNUElSOFpRY2JtS05Gb0U1WHJsQmIwUG1KN1o1QldkcDZMcGhZdVFHQlliZVk3aWhzZ2oxOHlFcTdCdFR4aTdfTQ?oc=5","date":"2025-07-30","type":"trial","source":"Ophthalmology Times Europe","summary":"Exonate announces CLEAR-DE trial for EXN407 - Ophthalmology Times Europe","headline":"Exonate announces CLEAR-DE trial for EXN407","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPR0NLY1VRT2l6UmdZdHRWMUlvRGo3X0dPSzdpZUk4UE5hWlhoRXVzeXY2OC1CalprbklHRy1RNjVVU2UzY3o3eDVfWC1DbGt5eklvNDRPRmpkSEJMZW1ZQ1V0MHhxVmdtWS1tbExSZVFLWDdpNG1EcEdrNnRxd0NqU0tfSGR4WVdaVVlYVVE2eGdRcmxmSVFDOWdTOGNpZw?oc=5","date":"2025-07-29","type":"trial","source":"PharmaTimes","summary":"Exonate to launch phase 2b trial of EXN407 for diabetic eye disease - PharmaTimes","headline":"Exonate to launch phase 2b trial of EXN407 for diabetic eye disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOOVJIenVNc1MxWVNqRWRocE9QdkZVbGd6WUl3endxV2FUeUJFeUJ0OGpRU2ZhaFZ0Q2RZZldicHhaLThBZ3BiblBzTjFRTERQdlA4bkZOMTE3UElFNUtZM1g1Ql9QZWJQbVpmYVVqMk50YV9hVENvWWwzQktIVHNNR3hoeW9haTlFakE1TURTY2luR3FJX3cxTDZOR0VOYTMxRGRydTllNnZMNlZnTmhCbnBfbDl5a1BSbG1zbnVXYWgzcmdx?oc=5","date":"2024-12-09","type":"regulatory","source":"modernretina.com","summary":"DelveInsight releases report of in-depth background and trends of the diabetic macular edema - modernretina.com","headline":"DelveInsight releases report of in-depth background and trends of the diabetic macular edema","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE9nU1ZVWTFTUXRfTVVFdVpwNGtsdmsydTdqcVBBblpwQmRPSV9Ta2IzQkdGWDFxODNBa3hJV1l5b0l2OWFnLWoyNnBNMHRXQTZ3RnNQNFN1ZFRObmdfRF9DZHpB?oc=5","date":"2024-07-16","type":"pipeline","source":"PharmaTimes","summary":"Dr Rafiq Hasan - PharmaTimes","headline":"Dr Rafiq Hasan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxPOXEyM3Zka1UwOHRHUXRQOHVwd3JwdlV0WlpqMnhIbHk4RkN1Y1FUaGRKT2UwNHRDUTBCTGd6VmhVTV8tZ3R4N0lmalVOOVphemNSRGpEdVZSMklyZ2dKLThGNkIyMkR0VXZBaHpETG1UaF9Nc2JzdFB1OF9nVnUxd1UyZjEweEJGTXVhNW5JUEF4RmJ3eEIwcWt0X2xzN2R4Qjl5aXpyZEtfNUF4dlk4bXlzZ09iU0RULUFKNEtEYm9lN1BhYm42QkJBcDY0SHVaRUc3dDBpYkhRY3ZZdDhhZ3k1Q0VzOHU3RWF6MmM3NDlyZU9MMUQtM0M5V3Jub1htN21zVlUwaEVUSHVlemdxdllQeWtpbXVmU3FxSWl0WnZHc3haSkFrQTFEOThTcDlXZjMyYw?oc=5","date":"2024-03-05","type":"regulatory","source":"News-Medical","summary":"Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema - News-Medical","headline":"Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTGRNWmh1TWNoWExzSzFLNzNxSVZVWllydHlwcE9BMDFQbmkxVFlDOGh2LUJqWVA0dVBsLVJ5VXF5UFZsZGpRN2hqVlg1MUNpWl9iZTkzcDBZTnBYS1hPUGUyWjg2NXJIUWRiQ1RsUHZ2STBnWm51LU5tVjVIbEtjbmF6QjZLalRqZDNFMnVBQWpVSjU0RWNrMGZBb20tOGdUV0dtZ1BUZW4?oc=5","date":"2021-02-03","type":"trial","source":"UNSW Sydney","summary":"Revolutionary eye drop trial starts for common eye diseases - UNSW Sydney","headline":"Revolutionary eye drop trial starts for common eye diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1rczFLdGZQaWVtZkNtTHhxS2VBUFlFcHBqODFYRXh6RE5CQkQ1dXpoX19oREtQZ0w1MVh3a2N0aTJqbXkzMENZSWYwTUJrZnNsbFd4c21oVTlVeE1LSl9PMUdWcGlzbTQ?oc=5","date":"2021-02-02","type":"pipeline","source":"University of Nottingham","summary":"News - First patient dosed with a new eye drop to treat one of the leading causes of blindness - University of Nottingham","headline":"News - First patient dosed with a new eye drop to treat one of the leading causes of blindness","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE43c21LTExtazR1R0dhanZCaVMzT0JBLTYySC1JS3hsMFpEb29iTllvV0VpWnVfa1VLTUp3OXlLREUxZHNkVUxwVVBfb3hfSTdvRkZIU1RYR2tuUQ?oc=5","date":"2020-01-13","type":"deal","source":"University of Nottingham","summary":"University of Nottingham Spin out secures major collaboration deal with Johnson and Johnson - University of Nottingham","headline":"University of Nottingham Spin out secures major collaboration deal with Johnson and Johnson","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}